IceCure Medical (ICCM) Reports 70% Surge in ProSense Cryoablation Install Base

The Quick Take

• IceCure Medical (ICCM) reported a 70% surge in its ProSense cryoablation system install base, validating accelerating clinical adoption of its non-surgical tumour treatment platform
• Each installed ProSense unit generates recurring revenue from consumable cryoprobe sales and procedure kits — a razor-and-blade model that converts install base growth into predictable revenue
• Reimbursement coverage expansion for breast fibroadenoma and kidney tumour cryoablation is the key variable for converting installed units into active clinical utilisation

IceCure Medical (ICCM) reported significant expansion in its ProSense cryoablation system install base, with sources noting a 70% surge in placements — a commercial milestone validating accelerating clinical adoption of IceCure's non-surgical tumour treatment platform. ProSense uses liquid nitrogen-based cryoablation to freeze and destroy solid tumours under ultrasound or CT guidance, offering an outpatient alternative to surgical excision for breast fibroadenomas, kidney tumours, and other accessible solid malignancies. A 70% install base expansion is meaningful for a commercial-stage medical device company because each installed unit generates recurring revenue from disposable cryoprobe sales and procedure kits — the razor-and-blade model that provides revenue predictability as the install base scales.

For oncology and minimally invasive procedure investors, IceCure's install base growth signals accelerating adoption among interventional radiologists and breast care specialists expanding office-based procedure capabilities. The structural shift toward outpatient cancer treatment — driven by healthcare payer preference for lower-cost settings and patient preference for less invasive approaches — benefits companies like IceCure that make imaging-guided ablation accessible outside hospital settings. IceCure's differentiation from competing cryoablation and radiofrequency ablation systems lies in its liquid nitrogen platform's simplicity, lower capital cost, and absence of active heating — enabling shorter procedure times in certain tumour geometries and making office deployment more practical for community-based oncologists.

The forward signal for ICCM is the conversion of install base growth into procedure volume revenue — unit economics improve significantly at higher device utilisation rates, and a 70% install base expansion only translates to proportional revenue if procedure volumes per site also grow. The macro variable is US commercial payer reimbursement expansion for cryoablation procedures: broader Medicare and commercial payer coverage decisions for breast fibroadenoma and kidney tumour ablation directly affect procedure volume growth and ICCM's revenue per installed unit. Watch IceCure's quarterly procedure volume disclosure alongside install base data to confirm the revenue model is converting unit placements into active clinical utilisation at scale.

Synthesized from 2 sources.